GLP-1 Skin Adverse Events: 8.16% of Semaglutide Reports in FDA Database of 129,330 Cases
Eight in every 100 semaglutide users in FDA’s adverse event database reported a skin reaction. A 2026 study in the Journal of Drugs in Dermatology analyzed 129,330 reports filed with the FDA Adverse Event Reporting System (FAERS) between 2018 and 2024, producing the first quantitative skin-side-effect profile for the GLP-1 class. With diet-driven GLP-1 prescriptions accelerating worldwide, the data deserve attention.
Study Design
Study: GLP-1 receptor agonist-associated cutaneous adverse events: A cross-sectional FAERS analysis.
Journal: Journal of Drugs in Dermatology, 2026.
Lead author: Marisa Fat, BS.
Data: FDA Adverse Event Reporting System (FAERS), January 2018-2024.
Total adverse event reports: 129,330.
Drugs analyzed: Semaglutide, liraglutide, exenatide, dulaglutide (with DPP-IV inhibitors as comparator).
Cutaneous Adverse Event Rates by Drug
| Drug | Brand Names | Skin AE Rate |
|---|---|---|
| Semaglutide | Ozempic / Wegovy | 8.16% |
| Liraglutide | Saxenda / Victoza | 7.66% |
| Exenatide | Byetta | 5.74% |
| Dulaglutide | Trulicity | 3.75% |
| GLP-1 (overall) | - | 5.75% |
| DPP-IV inhibitors | - | PRR 0.27 (fewer) |
Semaglutide and liraglutide, the two most widely prescribed agents for weight loss, also ranked first and second in skin-side-event frequency.
Most Common Skin Reactions (by frequency)
- Rash and pruritus (most common)
- Alopecia (under-discussed)
- Hyperhidrosis
- Urticaria/hypersensitivity reactions
The authors flagged alopecia in particular. Marisa Fat noted that “hair loss isn’t commonly discussed as a potential side effect” despite appearing repeatedly in the database.
Why Semaglutide Rises to the Top
Semaglutide and liraglutide share ~96-97% homology with native human GLP-1, which should reduce antigenicity. But they also account for the overwhelming majority of GLP-1 prescriptions, so absolute report counts scale with usage. FAERS is a voluntary reporting system, which amplifies this skew.
Even controlling for volume, the relative rates suggest a real structural component. Semaglutide’s 8.16% skin reaction rate is more than double dulaglutide’s 3.75%. Differences in molecular architecture may translate into different cutaneous behavior.
Alopecia and Telogen Effluvium
The leading mechanism behind GLP-1-associated hair loss is telogen effluvium. Rapid weight loss synchronizes the normally staggered hair cycle, pushing follicles into the resting (telogen) phase. About three months later, the hair sheds together. In users who lose 15-20% of body weight within six months, the pattern is common.
There is no direct pharmacologic intervention, but maintaining protein intake (1.2-1.6 g/kg body weight), iron, biotin, and zinc supports recovery. Slowing the rate of weight loss also reduces the cycle synchronization.
”Ozempic Face” Is a Separate Phenomenon
The cutaneous events in this analysis are surface reactions: rash, itch, hives, hair shedding. The widely reported “Ozempic face”—midface volume loss and skin laxity—is not a direct drug effect. It reflects subcutaneous fat depletion that accompanies any rapid weight loss. There is no clinical evidence that GLP-1 receptors directly suppress collagen or elastin synthesis.
That said, dermatologists are seeing reductions in facial dermal thickness in patients who lose more than 15 kg over 6-12 months on GLP-1s. The practical countermeasure is preserving lean mass with adequate protein and resistance training during the weight-loss phase.
Clinical Brief for Prescribers
- Screen for atopic and allergic skin history before initiating GLP-1.
- Counsel injection site rotation.
- Weekly formulations may be preferable to daily ones in skin-sensitive patients.
- Brief patients on possible alopecia early, so they don’t abandon therapy when shedding begins.
- Refer to dermatology if rash persists beyond three weeks or is accompanied by urticaria.
References
- Journal of Drugs in Dermatology, 2026
- Lead author: Marisa Fat (FAERS analysis)
- GLP-1 skin AE proportional reporting ratio vs DPP-IV inhibitors: 0.27 (lower)
- FAERS is voluntary; true incidence is likely higher
- Semaglutide = Ozempic (diabetes) / Wegovy (obesity)
- Liraglutide = Victoza (diabetes) / Saxenda (obesity)